BackNovo Nordisk A/S Class B Overview

Novo Nordisk A/S Class B Accounts Payable

Novo Nordisk A/S Class B's accounts payable is $150B.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$154.79B
↑ 448.79% YoYΔ $126.59B vs prior year quarter

Peer average

Loading

Novo Nordisk A/S Class B Accounts Payable History

Loading

Novo Nordisk A/S Class B vs. peers: Accounts Payable Comparison

Loading

Novo Nordisk A/S Class B Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Novo Nordisk A/S Class B (NONOF) FAQ

As of the most recent data (June 2026), NONOF shows a accounts payable of $150B. That compares with $28B in the prior-year period — up 448.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NONOF's accounts payable is now $150B (was $28B) — a 448.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk A/S Class B is outperforming or lagging.

Tracking NONOF's accounts payable over time shows whether Novo Nordisk A/S Class B is scaling, shrinking, or reshaping that part of the business. The current reading is $150B That compares with $28B in the prior-year period — up 448.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $150B) with ownership activity and broader fundamentals.

Novo Nordisk A/S Class B's accounts payable is $150B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.